Researchers evaluated the feasibility of using a personalized, tumor-informed circulating tumor DNA (ctDNA) assay to detect recurrence in patients with resectable pancreatic adenocarcinoma (PDAC). They successfully designed ctDNA assays for all patients, and found that ctDNA positivity during the immediate postoperative period was associated with significantly inferior recurrence-free survival and overall survival. This study demonstrates the potential of ctDNA as a prognostic tool for monitoring molecular residual disease and predicting recurrence in patients with PDAC.
Letter by Eckhoff AM, Kanu E (…) Allen PJ et 5 al. in Ann Surg Oncol
© 2024. Society of Surgical Oncology.